Cystic Fibrosis
"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Descriptor ID |
D003550
|
MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 | 2000 | 1 | 0 | 1 | 2004 | 1 | 1 | 2 | 2009 | 1 | 0 | 1 | 2014 | 1 | 0 | 1 | 2015 | 3 | 0 | 3 | 2018 | 1 | 0 | 1 | 2019 | 1 | 0 | 1 | 2021 | 1 | 0 | 1 | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Kanwar N, Harrison CJ, Pence MA, Qin X, Selvarangan R. Comparative in vitro antipseudomonal activity of ceftolozane/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis. Diagn Microbiol Infect Dis. 2023 Apr; 105(4):115904.
-
Nichols DP, Singh PK, Baines A, Caverly LJ, Chmiel JF, GIbson RL, Lascano J, Morgan SJ, Retsch-Bogart G, Saiman L, Sadeghi H, Billings JL, Heltshe SL, Kirby S, Kong A, Nick JA, Mayer-Hamblett N. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax. 2022 06; 77(6):581-588.
-
Bastarache L, Hughey JJ, Goldstein JA, Bastraache JA, Das S, Zaki NC, Zeng C, Tang LA, Roden DM, Denny JC. Improving the phenotype risk score as a scalable approach to identifying patients with Mendelian disease. J Am Med Inform Assoc. 2019 12 01; 26(12):1437-1447.
-
Jorth P, Ehsan Z, Rezayat A, Caldwell E, Pope C, Brewington JJ, Goss CH, Benscoter D, Clancy JP, Singh PK. Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis. Cell Rep. 2019 04 23; 27(4):1190-1204.e3.
-
Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611.
-
Ehsan Z, Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol. 2015; 10(12):1901-12.
-
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31.
-
Poppert KM, Patton SR, Borner KB, Davis AM, Dreyer Gillette ML. Systematic review: mealtime behavior measures used in pediatric chronic illness populations. J Pediatr Psychol. 2015 Jun; 40(5):475-86.
-
Ehsan Z, Wetzel JD, Clancy JP. Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Expert Opin Investig Drugs. 2014 May; 23(5):743-9.
-
Black PG, Derse AR, Derrington S, Lantos JD. Can a patient designate his doctor as his proxy decision maker? Pediatrics. 2013 May; 131(5):986-90.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|